Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Ord Shs (OP: TKPHF )

24.45 UNCHANGED
Streaming Delayed Price Updated: 3:13 PM EST, Dec 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Ord Shs

< Previous 1 2 Next >
Current Analysis: Takeda Pharmaceutical
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. Over the past year, Takeda’s share price fell 20.5% from $34.04 to $27.05 as of... 
Via Talk Markets
Current Analysis: Takeda Pharmaceuticals (TKPHF)
TKPHF is the largest Japanese drug company. Furthermore the estimated $45.50 dividend income from $1k invested is about 1.64 times greater than Friday’s price of a single share 
Via Talk Markets
Takeda Moves Out From Licensing Agreement With Theravance Biopharma
In its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it agreed to discontinue further development of TAK-954 for post-operative gastrointestinal dysfunction and the parties'... 
Via Benzinga
Takeda's FY22 Net Profit Jumps 38%, But Expects Lower FY23 Revenues
Takeda Pharmaceutical Co Ltd's (NYSE: TAK) FY22 net profit rose 37.8% to ¥317.02 billion, mainly due to solid growth in its  
Via Benzinga
United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review
The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003. 
Via Benzinga
Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B
Via Benzinga
Takeda's Dengue Vaccine Candidate Under FDA Priority Review
Via Benzinga
Takeda Posts Lower 1H Profit, Lifts FY22 Outlook
Via Benzinga
Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids
Via Benzinga
Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says
Via Benzinga
Takeda Presents Vedolizumab Data For Preventing Graft-Versus-Host Disease In Stem Cell Transplant Patients
Via Benzinga
Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged
Via Benzinga
Why Shares of Phathom Pharmaceutical Jumped This Week
Investors are reading between the lines to see if the company is fixing its problems regarding its lead therapy. 
Via The Motley Fool
Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study
Via Benzinga
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
From Singapore Economic Development Board (EDB)A*STAR
Via ACN Newswire
Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder
Via Benzinga
Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22
Via Benzinga
Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
Via Benzinga
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
Via Benzinga
After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact
Via Benzinga
EXCLUSIVE: Takeda's Cancer Partner BridGene Raises $38.5M To Accelerate Work On Undruggable Targets
BridGene Biosciences Inc has completed a $38.5 million Series B financing by Lapam Capital, Junson Capital, and Dyee Capital. The platform enables screening small molecules against the whole proteome... 
Via Benzinga
Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022. 
Via Benzinga
FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder
The  
Via Benzinga
Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients
Via Benzinga
Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection
Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise as a treatment for COVID... 
Via Benzinga
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly... 
Via Benzinga
Takeda Inks $2B Gene Therapy Pact With Code Biotherapeutics
Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed up for a gene therapy pact, encoding a $2 billion biobucks deal with Code Biotherapeutics across four... 
Via Benzinga
Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of... 
Via Benzinga
FDA Rejects Takeda's Eosinophilic Esophagitis Candidate, Asks For Additional Study
Takeda Pharmaceutical Co Ltd (NYSE: TAK) received a Complete Response Letter (CRL) from the FDA for its marketing application for TAK-721 (budesonide oral... 
Via Benzinga
Novavax Files For Approval Of Its COVID-19 Vaccine In Japan
Novavax Inc (NASDAQ: NVAX) has submitted a marketing application in Japan seeking approval for its COVID-19 vaccine by its partner Takeda Pharmaceutical Co Ltd... 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.